Intrinsic Value of S&P & Nasdaq Contact Us

Grifols, S.A. GRFS NASDAQ

NASDAQ Global Select • Healthcare • Drug Manufacturers - General • ES • USD

SharesGrow Score
62/100
3/7 Pass
SharesGrow Intrinsic Value
$50.59
+495.2%

Grifols, S.A. (GRFS) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 4 Buy, 2 Hold, 2 Sell.

Analysts estimate Earnings Per Share (EPS) of $0.59 and revenue of $7.23B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $0.23 vs est $0.59 (missed -61%). 2025: actual $0.57 vs est $0.72 (missed -21.2%). Analyst accuracy: 8%.

GRFS Analyst Ratings

Buy
8
Ratings
4 Buy
2 Hold
2 Sell
Based on 8 analysts giving stock ratings to Grifols, S.A. in the past 3 months
Rating breakdown
Buy
4 50%
Hold
2 25%
Sell
2 25%
50%
Buy
4 analysts
25%
Hold
2 analysts
25%
Sell
2 analysts

EPS Estimates — GRFS

8%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual $0.23 vs Est $0.59 ▼ 156.4% off
2025 Actual $0.57 vs Est $0.72 ▼ 26.8% off
Profitability Outlook
Company is profitable but with thin earnings per share. EPS trend is improving.

Revenue Estimates — GRFS

98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $7.212B vs Est $7.231B ▼ 0.3% off
2025 Actual $7.227B vs Est $7.504B ▼ 3.8% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message